Sanofi ranked first in the 2026 CNS Summit Digital Innovation Index, developed in collaboration with IDEA Pharma, a division of SAI MedPartners, placing in the top three in all three categories. The rankings were revealed today on the CNS Summit 2026 main stage at Encore Boston Harbor.
The 2026 top 10 are Sanofi, Eli Lilly, AstraZeneca, Chugai, Roche, Bristol Myers Squibb, Novo Nordisk, Johnson & Johnson, Boehringer Ingelheim and Merck KGaA. Category leaders were Roche in commercial, Novo Nordisk in clinical development and Recursion in research.
"Ranking first in the Pharmaceutical Digital Innovation Index reflects a shift we are proud of: digital and AI at Sanofi are now a connected system spanning research, clinical development and commercial operations. This is what allows us to move beyond AI experimentation to AI that delivers impact at scale, so that scientific breakthroughs reach patients faster," said Emmanuel Frenehard, Chief Digital Officer, Sanofi.
CNS Summit's Chairman and Chief Curator, Dr. Amir Kalali, said, "Digital innovation is becoming more and more important in research and development. We are pleased to continue to support this independent effort to benchmark the performance of life science companies in this area."
IDEA Pharma's Chief Medical Officer and SVP of Consulting, Dr. Alexander Gray, added, "Eleven years into the Digital Innovation Index, we're seeing a fundamental change in what defines digital leadership in pharma: it's not only about adopting new technologies but also about embedding them into the decisions that shape candidate selection, drug development and patient care. This year's leaders demonstrate the value of connecting innovation across research, clinical development and commercial operations, setting a new benchmark for the industry."